Dynavax hepatitis C drug brings antiviral response in early-stage trial

01/26/2010 | Reuters

An early-stage study showed that high doses of Dynavax Technologies' hepatitis C drug reduced the severity of viral infection in patients who also received other antivirals. The treatment, SD-101, outperformed older drugs in stimulating the production of two forms of interferons, which help the immune system fight viruses and other pathogens.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA